Galantamine therapy in dementia associated with CADASIL

Cholinergic neuronal impairment has been suggested in cerebral autosomal dominant arteriopathy with subcortical infarcts and leucoencefalopathy (CADASIL). Cholinomimetic therapy could be useful. Four patients with CADASIL and dementia were treated with the acetylcholinesterase inhibitor galantamine...

Full description

Saved in:
Bibliographic Details
Published inRevista de neurologiá Vol. 47; no. 6; pp. 299 - 300
Main Authors Posada, I J, Ferrero, M, Lopez-Valdes, E, Goni-Imizcoz, M
Format Journal Article
LanguageSpanish
Published Spain 16.09.2008
Subjects
Aged
CADASIL - complications
CADASIL - drug therapy
CADASIL - genetics
Caregivers
Cholinesterase Inhibitors - therapeutic use
Dementia - drug therapy
Dementia - etiology
Female
Galantamine - therapeutic use
Humans
Male
Middle Aged
Nootropic Agents - therapeutic use
Online AccessGet full text

Cover

More Information
Summary:Cholinergic neuronal impairment has been suggested in cerebral autosomal dominant arteriopathy with subcortical infarcts and leucoencefalopathy (CADASIL). Cholinomimetic therapy could be useful. Four patients with CADASIL and dementia were treated with the acetylcholinesterase inhibitor galantamine and we assessed cognitive, behavioral, functional and the caregiver burden aspects. Three patients showed either mild improvement or stabilization in the behavior and caregiver burden. Our results suggest some benefit from galantamine treatment and they could support the existence of a cholinergic deficit in CADASIL.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ObjectType-Report-3
ObjectType-Case Study-4
ISSN:1576-6578
DOI:10.33588/rn.4706.2008234